DOSSIER · 13F-HR · Q1 2026

Catalys Pacific, LLC

$231M in tracked AUM across 2 positions as of Q1 2026.

CP
CIK 0002011385 · last filed Mar 31, 2026
Total AUM
$231M
as of Q1 2026
Holdings
2
positions
Whale Score
69
69
tracked
Activity
no data
changes this Q
AI Analysis · Q1 2026

Portfolio Overview

Catalys Pacific, LLC’s 13F filing for the period ending September 30, 2025, reveals a dramatic transformation in the firm's portfolio structure and risk profile. The total portfolio value plummeted by 89.6%, decreasing from $131.66 million in the previous quarter to $13.74 million. This drastic reduction in assets under management (AUM) suggests a significant liquidity event, such as a large capital return to investors, or a substantial pivot in strategy.

Fur...

Key Holdings

The portfolio is composed entirely of Phathom Pharmaceuticals, Inc., which accounts for 100% of the total value at $13.74 million. The position consists of 1.17 million shares.

Quarter at a glance — Q1 2026

Position-change comparison pending.

No quarter-over-quarter changes available.

Top 10 holdings

By portfolio weight as of Q1 2026.

#HoldingValueSharesWeight
01
MLYS
Mineralys Therapeutics, Inc.
$214M7.9M92.8%
02
PHAT
Phathom Pharmaceuticals, Inc.
$17M1.5M7.2%

Filing history

2026Q1Mar 31
$231M 25.7%
2 positionsView →
2025Q4Dec 31
$311M 2160.6%
2 positionsView →
2025Q3Sep 30
$14M 89.6%
1 positionsView →
2025Q2Jun 30
$132M 11.5%
2 positionsLocked
2025Q1Mar 31
$149M 28.3%
2 positionsLocked
2024Q4Dec 31
$116M 7.6%
2 positionsLocked
2024Q3Sep 30
$125M 5.4%
3 positionsLocked
2024Q2Jun 30
$132M 10.6%
3 positionsLocked
2024Q1Mar 31
$148M 38.9%
3 positionsLocked
2023Q4Dec 31
$107M
3 positionsLocked